+

WO2007066189A3 - Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea - Google Patents

Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea Download PDF

Info

Publication number
WO2007066189A3
WO2007066189A3 PCT/IB2006/003416 IB2006003416W WO2007066189A3 WO 2007066189 A3 WO2007066189 A3 WO 2007066189A3 IB 2006003416 W IB2006003416 W IB 2006003416W WO 2007066189 A3 WO2007066189 A3 WO 2007066189A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
pyrrolo
prodrugs
dichloro
pyrimidine
Prior art date
Application number
PCT/IB2006/003416
Other languages
French (fr)
Other versions
WO2007066189A2 (en
Inventor
Tracy Lee Boyden
Feng Guo
Susan Deborah Lagreca
Douglas Alan Lorenz
Ravi Mysore Shanker
Franzanne Vreeland
Original Assignee
Pfizer Prod Inc
Tracy Lee Boyden
Feng Guo
Susan Deborah Lagreca
Douglas Alan Lorenz
Ravi Mysore Shanker
Franzanne Vreeland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Tracy Lee Boyden, Feng Guo, Susan Deborah Lagreca, Douglas Alan Lorenz, Ravi Mysore Shanker, Franzanne Vreeland filed Critical Pfizer Prod Inc
Publication of WO2007066189A2 publication Critical patent/WO2007066189A2/en
Publication of WO2007066189A3 publication Critical patent/WO2007066189A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to compounds of the formula (I), or a pharmaceutically acceptable salt, prodrug or hydrates thereof. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula (I).
PCT/IB2006/003416 2005-12-09 2006-11-24 Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea WO2007066189A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09
US60/749,070 2005-12-09

Publications (2)

Publication Number Publication Date
WO2007066189A2 WO2007066189A2 (en) 2007-06-14
WO2007066189A3 true WO2007066189A3 (en) 2008-08-14

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003416 WO2007066189A2 (en) 2005-12-09 2006-11-24 Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea

Country Status (8)

Country Link
AR (1) AR058293A1 (en)
DO (1) DOP2006000271A (en)
GT (1) GT200600496A (en)
NL (1) NL2000337A1 (en)
PE (1) PE20071037A1 (en)
TW (1) TW200733965A (en)
UY (1) UY29991A1 (en)
WO (1) WO2007066189A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197426A2 (en) * 2007-10-19 2010-06-23 Abbott GmbH & Co. KG Solid dispersion product containing n-aryl urea-based compound
KR20100087170A (en) * 2007-10-19 2010-08-03 애보트 게엠베하 운트 콤파니 카게 Solid dispersion product of n-aryl urea-based drugs
JP5819195B2 (en) * 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Fusion ring heteroaryl kinase inhibitors
CA2785716A1 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
CA2802541A1 (en) * 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2986610B9 (en) 2013-04-19 2018-10-17 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
MY197720A (en) 2015-02-20 2023-07-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN107722012B (en) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
KR20210018265A (en) 2018-05-04 2021-02-17 인사이트 코포레이션 Solid form of FGFR inhibitor and method for preparing same
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CR20220169A (en) 2019-10-14 2022-10-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (en) 2021-04-12 2023-02-01 美商英塞特公司 Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
TW202313611A (en) 2021-06-09 2023-04-01 美商英塞特公司 Tricyclic heterocycles as fgfr inhibitors
JP2025015449A (en) * 2023-07-18 2025-01-30 信越化学工業株式会社 Composition for solid dispersion, solid dispersion, and method of manufacturing solid dispersion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786A2 (en) * 1997-08-11 1999-03-17 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
WO2004056830A1 (en) * 2002-12-19 2004-07-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786A2 (en) * 1997-08-11 1999-03-17 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
WO2004056830A1 (en) * 2002-12-19 2004-07-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1

Also Published As

Publication number Publication date
PE20071037A1 (en) 2007-11-19
GT200600496A (en) 2007-07-17
WO2007066189A2 (en) 2007-06-14
AR058293A1 (en) 2008-01-30
UY29991A1 (en) 2007-07-31
NL2000337A1 (en) 2007-06-12
DOP2006000271A (en) 2007-08-15
TW200733965A (en) 2007-09-16

Similar Documents

Publication Publication Date Title
WO2007066189A3 (en) Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
CA2510853A1 (en) Pyrrolopyrimidine derivatives
WO2007138472A3 (en) Triazolopyridazine derivatives
NO20085060L (en) Triazole pyrazine derivatives useful as anti-cancer agents
MXPA06002296A (en) Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents.
WO2008020040A3 (en) 2,5-dihydroxybenzene compounds for the treatment of fibrosis
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
WO2007056167A3 (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
WO2003063864A3 (en) Heterocyclic compounds which are active as inhibitors of beta lactamases
WO2007031933A3 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
TW200728307A (en) Novel spirochromanone derivatives
MXPA02012034A (en) Thiophene derivatives useful as anticancer agents.
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
NO20065078L (en) Inhalation powder formulations containing enantiomerically pure beta agonists.
WO2006077024A3 (en) 5-aminoindole derivatives
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
MX2009007038A (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders.
WO2006078724A3 (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
TW200626158A (en) Naphthaline derivatives
WO2006103545A8 (en) 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
WO2006103544A8 (en) 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06821007

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06821007

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载